Eplerenone is a selective aldosterone receptor antagonist used primarily to treat hypertension and heart failure with reduced ejection fraction (HFrEF). Unlike abacavir, which is an antiretroviral nucleoside reverse transcriptase inhibitor for HIV, eplerenone works by blocking aldosterone receptors in the distal renal tubules. This leads to increased sodium and water excretion while conserving potassium, helping to lower blood pressure and reduce fluid overload in heart failure. Eplerenone was developed in the 1980s–1990s as a more selective alternative to spironolactone, with fewer endocrine side effects such as gynecomastia. It is commonly used as part of combination therapy for cardiovascular conditions and requires monitoring of serum potassium and renal functionduring treatment.
BRAND NAMES
Inspra – the most widely recognized brand name for eplerenone, used for hypertension and heart failure with reduced ejection fraction (HFrEF).
Generic eplerenone – available in various countries under the generic name, often in 25 mg and 50 mg tablets.
MECHANISM OF ACTION
Eplerenone is a selective aldosterone receptor antagonist that works by blocking mineralocorticoid (aldosterone) receptors in the distal renal tubules. By inhibiting aldosterone, eplerenone reduces sodium and water reabsorption while conserving potassium, leading to decreased blood volume and lower blood pressure.
PHARMACOKINETICS
Absorption
plerenone is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 1.5 to 2 hours post-dose. Its absolute bioavailability is around 69%, and absorption is not significantly affected by food, though taking it with food may slightly delay peak levels.
Distribution
Eplerenone has a moderate volume of distribution, approximately 50 liters, indicating that it distributes beyond the plasma into tissues but does not extensively accumulate in fat.
Metabolism
Eplerenone is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4, into inactive metabolites. This hepatic metabolism accounts for most of the drug’s clearance, and because of this, strong CYP3A4 inhibitors or inducers can significantly alter eplerenone plasma levels.
Elimination
Eplerenone and its metabolites are primarily excreted via the urine (approximately 67%) and to a lesser extent in feces (about 32%). The drug has an elimination half-life of roughly 4–6 hours, allowing for once- or twice-daily dosing.
PHARMACODYNAMICS
Eplerenone exerts its pharmacologic effects by selectively blocking mineralocorticoid (aldosterone) receptors in the distal renal tubules and cardiovascular tissues. This antagonism reduces sodium and water reabsorption while conserving potassium, leading to decreased blood volume and lower blood pressure.
ADMINISTRATION
Eplerenone is administered orally in tablet form, usually available in 25 mg and 50 mg tablets. It is typically taken once or twice daily depending on the indication: for hypertension, a lower starting dose is often used, while for heart failure with reduced ejection fraction (HFrEF), the dose is gradually titrated to achieve optimal therapeutic effect.
DOSAGE AND STRENGTH
Eplerenone is available in 25 mg and 50 mg oral tablets. The recommended starting dose for hypertension is usually 50 mg once daily, which may be adjusted based on blood pressure response.
DRUG INTERACTIONS
Eplerenone has significant potential for drug interactions due to its metabolism via CYP3A4. Co-administration with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin can increase plasma levels of eplerenone, heightening the risk of hyperkalemia and hypotension.
FOOD INTERACTIONS
Eplerenone can be taken with or without food, as food does not significantly affect its absorption or bioavailability. There are no specific dietary restrictions required for its use.
CONTRAINDICATIONS
Eplerenone is contraindicated in patients with hyperkalemia, severe renal impairment, or severe hepatic impairment due to the risk of potassium accumulation and reduced drug metabolism. It should not be used in individuals with a known hypersensitivity to eplerenone or any component of the formulation.
SIDE EFFECTS
Hyperkalemia – elevated potassium levels, potentially serious
Hypotension – low blood pressure, especially in volume-depleted patients
Dizziness – often related to blood pressure changes
Fatigue – mild and generally transient
Headache – occasional
Diarrhea – uncommon
TOXICITY
Eplerenone has a favorable safety profile, but toxicity primarily arises from excessive potassium retention, leading to hyperkalemia, which can be life-threatening if severe. Other toxic effects may include hypotension, dizziness, fatigue, and electrolyte imbalances. The risk of toxicity increases in patients with renal or hepatic impairment, those taking CYP3A4 inhibitors, or in combination with other potassium-sparing drugs.
